Abstracts tagged "treatment and vasculitis"

Abstract Number: 212 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Large Vessel Arteritis (Giant Cell Arteritis and Temporal Arteritis): Findings from a Large Contemporaneous Real-World Cohort in the US
Zhaohui Su¹, Vandana Menon¹, Richard Gliklich² and Tom Brecht¹, ¹Research, OM1, Inc, Cambridge, MA, ²OM1, Inc, Cambridge, MA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis with annual incidence as high as 27 per 100,000 in persons…
Abstract Number: 779 • 2017 ACR/ARHP Annual Meeting
Assessment of Treatment Response By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Large Vessel Vasculitis (LVV)
Shubhasree Banerjee¹, Sara Alehashemi², Ali Cahid Civelek³, Elaine Novakovich⁴, Armin Bagheri⁵, Ashkan Malayeri³, Mark Ahlman³ and Peter C. Grayson⁶, ¹Fellowship and training branch, NIAMS/NIH, Bethesda, MD, ²Rheumatology, National Institutes of Health, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, ⁵Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, ⁶Research, National Institutes of Health, Bethesda, MD
Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serological (ESR, CRP) parameters. Imaging assessment, including FDG-PET, may also be…
Abstract Number: 894 • 2017 ACR/ARHP Annual Meeting
All Oral Interferon-Free Antivirals for Hepatitis C Virus Cryoglobulinemia Vasculitis: A Long Term Follow up Multicenter International Study
Patrice Cacoub¹, Si Nafa Si Ahmed², Yasmina FerFar³, SN Pol⁴, Dominique Thabut⁵, Christophe Hezode⁶, Laurent Albric⁷, Cloé Comarmond^8,9,10, Gafaar Ragab¹¹, Luca Quartuccio¹², Mohamed Hegazy¹³, Thierry Poynard⁵, Mathieu Resche-Rigon¹⁴ and David Saadoun¹⁵, ¹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ²Hôpital Orléans, Orléans, France, ³Internal Medicine, Hopital Pitié-Salpetrière, Paris, France, ⁴Department of Hepatology, APHP, Hôpital Cochin, Paris, paris, France, ⁵Groupe Hospitalier Pitié-Salpétrière, Paris, France, ⁶Hôpital Henri Mondor, Creteil, France, ⁷Centre hospitalier universitaire Purpan, Purpan, France, ⁸Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ⁹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁰Internal Medicine, Hôpital Pitié Salpétrière, Paris, France, ¹¹Cairo University, Cairo, Egypt, ¹²University Hospital "Santa Maria della Misericordia, Udine, Italy, ¹³Faculty of Medicine – Cairo University, Cairo, El Salvador, ¹⁴Hôpital Saint-Louis, Paris, France, ¹⁵Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
Background/Purpose: Interferon (IFN) containing regimens used for hepatitis C virus (HCV)-cryoglobulinemia vasculitis (CryoVas) are poorly effective and associated with important side effects. In small-size and…
Abstract Number: 1767 • 2017 ACR/ARHP Annual Meeting
The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months
Gunnar Tomasson¹, Antoine G. Sreih², David Cuthbertson³, Simon Carette⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Philip Seo¹¹, Ulrich Specks¹², Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹University of Iceland, Faculty of Medicine, Reykjavik, IS, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Medicine, Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic College of Medicine, Rochester, MN, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Standard management of ANCA-associated vasculitis (AAV) involves treatment with immunosuppressive agents for at least 18 months. Treatment beyond 18 months reduces the rates of…
Abstract Number: 17L • 2016 ACR/ARHP Annual Meeting
Sofosbuvir Plus Daclatasvir for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis
David Saadoun¹, yasmina ferfar¹, AS Bouyer², laurent alric³, christophe hezode⁴, SN Si Ahmed⁵, L Musset⁶, Luc De Saint Martin Pernot⁷, SN Pol⁸, Dominique Larrey⁹, T Poynard¹⁰ and Patrice Cacoub², ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ²Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, paris, France, ³Department of Internal Medicine-Digestive, Centre hospitalier universitaire Purpan, UMR 152 Toulouse 3 University, Toulouse, toulouse, France, ⁴Department of Hepatology, APHP, Hôpital Henri Mondor, Créteil, creteil, France, ⁵Department of Hepatology, Hôpital Orléans, Orléans, Orleans, France, ⁶Department of Immunology, UF d’Immunochimie et d’autoimmunité, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, France, paris, France, ⁷Department of internal medicine, CHRU Brest, Brest, France, ⁸Department of Hepatology, APHP, Hôpital Cochin, Paris, paris, France, ⁹Department of hepatology, CHRU Montpellier, France, montpellier, France, ¹⁰Department of Hepatology, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, paris, France

Background/Purpose: Hepatitis C virus (HCV) is the aetiological agent for most cases of cryoglobulinemia vasculitis. Interferon containing regimens are associated with important side effects and…
Abstract Number: 861 • 2016 ACR/ARHP Annual Meeting
Efficacy of Methotrexate in Giant Cell Arteritis
Matthew J. Koster¹, Cynthia S. Crowson², Cristian Labarca³, Francesco Muratore⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ⁴Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Prospective trials evaluating methotrexate (MTX) as adjunct immunosuppression in giant cell arteritis (GCA) have provided evidence of a modest benefit for reducing risk of…
Abstract Number: 979 • 2016 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Takayasu’s Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol A McAlear¹³, Kenneth J. Warrington³, Christian Pagnoux¹⁴, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess⁹, Gary S. Hoffman¹⁶, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Hospital for Special Surgery, Cornell, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Takayasu’s arteritis (TAK) is a large-vessel primary systemic vasculitis that affects the aorta, its branches, and the pulmonary arteries. Despite treatment with glucocorticoids, relapse…
Abstract Number: 1944 • 2016 ACR/ARHP Annual Meeting
Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis
Zachary Wallace¹, Eli Miloslavsky², Sebastian H. Unizony³, Na Lu⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol A. Langford⁷, Peter A. Merkel⁸, Paul A. Monach⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene William St.Clair¹², Paul Bruntetta¹³, Matthew Cascino¹⁴, Hyon K. Choi¹⁵ and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, Cornell, New York, NY, ¹²Rheumatology and Immunology, Duke University, Durham, NC, ¹³Genentech, Inc., South San Francisco, CA, ¹⁴University of California-San Francisco, San Francisco, CA, ¹⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) treatment includes high dose glucocorticoids (GCs), which are associated with increased body-mass index (BMI), a complication abhorred by patients and associated…
Abstract Number: 2950 • 2016 ACR/ARHP Annual Meeting
Cogan Syndrome: Treatment and Outcome from French Nationwide Retrospective Study and Literature Review of 62 Patients
CHARLOTTE DURTETTE¹, Mathieu Resche Regon², eric hachulla³, anne Graslands⁴, Thomas Papo^5,6, Jacques Pouchot⁷, jean Emmanuel kahn⁸, Thierry Zenone⁹, cedric landron¹⁰, benoit de Wazieres¹¹, Robin Dhote¹², Christophe Deligny¹³, Guillaume Gondran¹⁴, Edouard Pertuiset¹⁵, thomas quemeneur¹⁶, Bertrand Lioger¹⁷, Pascal Sève¹⁸, Christian Lavigne¹⁹, thomas le Galllou²⁰, Mohamed Hamidou²¹, claire delaunay²², Olivier Fain²³ and Arsene Mekinian²⁴, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²biostatistics Saint Louis Hospital, paris, France, ³chru lille hospital, lille, France, ⁴Service de Médecine interne, Hôpital Louis-Mourier, colombes, France, ⁵Department of Internal Medicine, AP-HP Bichat Hospital, Paris, France, ⁶Internal Medicine, Hôpital Bichat, Université Paris-Diderot, Paris, France, ⁷Paris University, Internal medicine, Paris, France, ⁸foch hospital, foch, France, ⁹Internal Medicine, Valence Hospital, Valence, France, ¹⁰service de médecine interne, CH Poitiers, CHU Poitiers, poitiers, France, ¹¹CHU de Nîmes, nimes, France, ¹²Internal Medicine, Hospital Avicenne, Bobigny, France, ¹³Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁴Internal Medicine Department, Limoges, France, ¹⁵CH René Dubos, Pontoise, France, ¹⁶valenciennes hospital, valenciennes, France, ¹⁷INTERNAL MEDICINE, tours, France, ¹⁸Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ¹⁹CHU Angers, department of Internal Medicine, Angers, France, ²⁰rennes CHU hospital, rennes, France, ²¹Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ²²Centre hospitalier niort, niort, France, ²³Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁴DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France
Background/Purpose: Methods: Sixty two patients were included with median age 37 [2-76] and 31/62 (50%) women. At the diagnosis, 61 (98%) had audiovestibular involvement,…
Abstract Number: 2977 • 2016 ACR/ARHP Annual Meeting
Treatment of Cryoglobulinemic Vasculitis with Sofosbuvir in Four Combination Protocols
Mohamed Tharwat Hegazy¹, Mohamed A Hussein¹, Luca Quartuccio², Mary Fawzy¹, Naguib Zoheir³, Mona I. Ellawindi⁴, Milena Bond², Cesare Mazzaro⁵, Ahmed El Ray⁶, Maissa El Said El Raziky^7,8, Magdy El Serafy⁹, Wahid Doss⁹, Patrice Cacoub¹⁰, Loïc Guillevin¹¹, Salvatore De Vita², Sherif El Khamisy¹² and Gaafar Ragab¹, ¹Internal Medicine, Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ²Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ³Clinical and Chemical Pathology Department, Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Community Medicine, Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁵Internal Medicine, Pordenone Hospital, Italy, pordenone, Italy, ⁶Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, ⁷Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, ⁸Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, ⁹Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ¹²Zewail city of Science and Technology, Egypt, Giza, Egypt
Background/Purpose: Cryoglobulinemic Vasculitis (CV) is a systemic vasculitis affecting small and medium-sized vessels. Following emergence of direct acting antiviral drugs, which paved the way to…
Abstract Number: 9L • 2015 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol McAlear¹³, Kenneth J. Warrington¹⁴, Christian Pagnoux⁶, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess¹⁶, Gary S. Hoffman¹, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel primary systemic vasculitis. Although glucocorticoids are effective in treating GCA, they are associated with substantial toxicity and…
Abstract Number: 886 • 2015 ACR/ARHP Annual Meeting
Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis
Sophia Lionaki¹, George Fragoulis², Aliki Venetsanopoulou², Panayiotis Vlachoyiannopoulos², John Boletis¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas², ¹Nephrology, Laiko Hospital, Department of Nephrology, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: To evaluate the long term outcomes, of patients with multi-relapsing Antineutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis (AAV), who received induction therapy with a rituximab…
Abstract Number: 888 • 2015 ACR/ARHP Annual Meeting
Plasma Exchanges to Treat Primary Systemic Necrotizing Vasculitides: Data from a French Nationwide Study
Gonzalo De Luna¹, Dominique Chauveau², Julien Aniort³, Pierre-Louis Carron⁴, Pierre Gobert⁵, Alexandre Karras⁶, Sylvain Adam-Marchand⁷, Francois Maurier⁸, Pierre-Yves Hatron⁹, Alexandre Mania¹⁰, Guillaume Le Guenno¹¹, Stéphane Ballly¹², Boris Bienvenu¹³, Eric Cardineau¹⁴, Tiphaine Goulenok¹⁵, Noémie Jourde-Chiche Sr.¹⁶, Maxime Samson¹⁷, Antoine Huart¹⁸, Jacques Pourrat¹⁹, Aurelien Tiple²⁰, Olivier Aumaître²¹, Xavier Puéchal²², Farhad Heshmati²³, Claire Le Jeunne²⁴, Luc Mouthon²⁵, Loïc Guillevin²⁶ and Benjamin Terrier²², ¹Medecine Interne, Cochin University Hospital, Paris, France, ²CH Toulouse, Toulouse, France, ³CHU, Clermont-Ferrand, France, ⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ⁵Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ⁶George Pompidou European Hospital, Paris, France, ⁷Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁰Hôpital Gabriel Montpied, Clermont-Ferrand, France, ¹¹Internal Medicine department, Clermont-Ferrand, France, ¹²CH, Chambéry, France, ¹³Internal Medicine, Hospital Caen, Caen, France, ¹⁴CH, Alencon, France, ¹⁵University Paris Diderot - APHP - Bichat Hospital, aris, France, ¹⁶Nephrology, Aix-Marseille Université - APHM, Marseille, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁸CHU, Toulouse, France, ¹⁹Nephrology, Rangeuil Hospital, Paris, France, ²⁰Nephrology, CHU, Clermont-Ferrand, France, ²¹Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²³Cochin Hospital, Paris, France, ²⁴Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ²⁵Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ²⁶Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Plasma exchange (PE) is usually used to treat severe primary systemic necrotizing vasculitides (SNVs) and/or virus-induced vasculitides. Only severe renal insufficiency (serum creatinine (SCR)…
Abstract Number: 890 • 2015 ACR/ARHP Annual Meeting
Anti-IgE Monoclonal Antibody in Refractory and/or Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss): Data from 17 Patients
Marie Jachiet¹, Maxime Samson², Vincent Cottin³, Jean-Emmanuel Kahn⁴, Guillaume Le Guenno⁵, Philippe Bonniaud⁶, Laurence Bouillet⁷, Anne Gondouin⁸, Fatma Makhlouf⁷, Nadine Meaux Ruault⁹, Helder Gil⁸, Hervé Devilliers¹⁰, Boris Bienvenu¹¹, André Coste¹², Violaine Giraud¹³, Stephane Dominique¹⁴, Bertrand Godeau¹⁵, Xavier Puéchal¹⁶, Chahéra Khouatra¹⁷, Marc Ruivard¹⁸, Claire Le Jeunne¹⁹, Luc Mouthon²⁰, Loïc Guillevin²¹ and Benjamin Terrier¹⁶, ¹Dermatology, Cochin Hospital, Paris, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine department, Clermont-Ferrand, France, ⁶CHU, Dijon, France, ⁷CHU, Grenoble, France, ⁸CHU, Besancon, France, ⁹Internal Medicine and Clinical Immunology, CHU de Besançon, Besançon, France, ¹⁰Department of Internal Medicine and Systemic Diseases, Dijon University Hospital, Dijon, France, ¹¹Internal Medicine, Hospital Caen, Caen, France, ¹²CHI, Créteil, France, ¹³Hôpital Ambroise Paré, Boulogne Billancourt, France, ¹⁴Pneumology, Rouen University Hospital, Rouen, France, ¹⁵Henri Mondor, Créteil, France, ¹⁶Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ¹⁷CHU Lyon, Lyon, France, ¹⁸CHU Clermont-Ferrand, Clermont–Ferrand, France, ¹⁹Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ²⁰Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ²¹Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Omalizumab, an anti-IgE monoclonal antibody, has proven efficacy for the treatment of moderate-to-severe and severe-persistent allergic asthma and allergic rhinitis, with a favorable safety…
Abstract Number: 3228 • 2015 ACR/ARHP Annual Meeting
Sofosbuvir Plus Ribavirin for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis: Vascuvaldic Study
David Saadoun¹, V Thibault², L Alric³, C Guillaud⁴, H Izzedine², M Costopoulos², L Musset², H Fontaine⁵, C Hezode⁴, S Pol⁵, T Poynard², P Cacoub² and SN SI Ahmed⁶, ¹Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, ²CHU Pitie Salpetriere, Paris, France, ³CHU Toulouse, Toulouse, France, ⁴CHU H Mondor, Creteil, France, ⁵CHU Cochin, Paris, France, ⁶CH Orleans, Orleans, France
Background/Purpose: Hepatitis C virus (HCV) is the etiologic agent for most cases of cryoglobulinemia vasculitis (Cryovas). Interferon–containing regimens are associated with important side effects and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].